Opposing the sharing of its intellectual property, the company’s board argued that “vaccine manufacturing is a biological production that is extraordinarily complex”, involving 280 ingredients from 86 suppliers in 19 countries. They added there was a risk to patients if other manufacturers were not able to meet all the requirements to make its vaccines properly.
